The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency has issued precautions in men. There is some evidence to suggest that men using valproate in the three months prior to the conception of a child, may have an increased risk of fathering children with neurodevelopmental disorders.

Based on a retrospective observational study that manufacturers of valproate were obliged to perform, as well as other sources, the PRAC has recommended as a precautionary measure that couples planning to conceive should use reliable contraception for three months after discontinuing valproate in the male partner.

You can find the full precaution on the European Medicines Agency site.